ANXA2 and breast cancer: Indeed, ANXA2 has been proved to sustain EMT and invasion of pancreatic ductal adenocarcinoma [41], induce hepatocellular carcinoma and breast cancer metastasis [20, 42] and was found up-regulated in highly invasive carcinomas [43–45].